Patent EP0442724A2 successfully refreshed from Google Patents.
EP0442724A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Modified hIL-6
Assignee: Amgen K A Inc
•
Filing: 1991-02-13
•
Granted: —
•
Expires: 2011-02-13
Abstract
Abstract Provided are PEGylated "interleukin-6" derivatives (PEG-IL-6) having an extended plasma half-life, as well as enhanced in vivo IL-6 biological activities. Methods for producing the modified glycosylated and unglycosylated IL-6 proteins or polypeptides, as well as, for their use in treating hematopoietic disorders and difficiencies, particularly acute thrombocytopenia, are also provided.
Inventors
- 👤 Toshifumi Mikayama
- 👤 Toshihiko Kadoya
- 👤 Makoto Kakitani
- 👤 Hideo Inoue
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 22:45
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/5412; A; A61; A61P; A61P7/00; A61K; A61K38/00; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
4 words
PEG-IL-6 having biological activity.
Claim 2
Dependent Claim
19 words
PEG-IL-6 according to claim 1 wherein said IL-6 is glycosylated IL-6, unglycosylated IL-6 or a biologically active fragment thereof.
Claim 3
Dependent Claim
31 words
PEG-IL-6 according to claim 2 wherein said IL-6 comprises a sequence of amino acids as defined in the Sequence Listing by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3.
Claim 4
Dependent Claim
20 words
PEG-IL-6 according to any one of the preceding claims, wherein said IL-6 is a naturally produced or synthetically produced IL-6.
Claim 5
Dependent Claim
39 words
PEG-IL-6 according to claim 4 wherein said naturally produced IL-6 is obtainable as an expression product of a prokaryotic or eukaryotic host cell transformed or transfected with a DNA sequence encoding IL-6 or encoding a biologically active IL-6 fragment.
Claim 6
Dependent Claim
12 words
PEG-IL-6 according to claim 5 wherein said host cell is E. coli.
Claim 7
Dependent Claim
17 words
PEG-IL-6 according to any one of the preceding claims wherein said PEG is obtainable from activated PEG.
Claim 8
Dependent Claim
23 words
PEG-IL-6 according to claim 7 wherein said activated PEG is the succinimidyl succinate derivative of PEG or the bis-PEG derivative of cyanuric chloride.
Claim 9
Dependent Claim
15 words
PEG-IL-6 according to claim 7 wherein said activated PEG is activated PEG1, PEG2 or PEG12M.
Claim 10
Dependent Claim
26 words
PEG-IL-6 according to any one of the preceding claims wherein the PEG is attached to the IL-6 via one or more amino groups on said IL-6.
Claim 11
Dependent Claim
23 words
PEG-IL-6 according to claim 10 wherein at least one hydrogen atom of said amino group on said IL-6 is substituted with said PEG.
Claim 12
Dependent Claim
19 words
PEG-IL-6 according to claim 10 wherein at least one amino group on said IL-6 is substituted with said PEG.
Claim 13
Dependent Claim
24 words
PEG-IL-6 according to any one of claims 1 to 9, wherein said PEG is attached via one or more carboxyl groups on said IL-6.
Claim 14
Dependent Claim
19 words
PEG-IL-6 according to claim 13 wherein at least one carboxyl group on said IL-6 is substituted with said PEG.
Claim 15
Dependent Claim
15 words
PEG-IL-6 according to any one of the preceding claims selected from PEG1-IL-6, PEG2-IL-6 and PEG12M-IL-6.
Claim 16
Dependent Claim
21 words
PEG-IL-6 according to claim 15, wherein the PEG1-IL-6 is PEG(4500)IL-6, the PEG2-IL-6 is PEG(10000)IL-6, and the PEG12M-IL-6 is PEG(12000)IL-6 or PEG(12000)IL-6′.
Claim 17
Dependent Claim
53 words
PEG-IL-6 according to claim 16, wherein the PEG(4500)IL-6 is selected from Fr45-0, Fr45-1, Fr45-2, Fr45-3, Fr45-4 or Fr45-5; the PEG(10000)IL-6 is selected from Fr100-0, Fr100-1, Fr100-2, Fr100-3, Fr100-4 or Fr100-5; the PEG(12000)IL-6 is selected from Fr120-1, Fr120-2, Fr120-3, Fr120-4 or Fr120-5; and the PEG(12000)IL-6′ is selected from Fr120′-1, Fr120′-2, Fr120′-3, Fr120′-4 or Fr120′-5.
Claim 18
Dependent Claim
21 words
PEG-IL-6 as claimed in any one of the preceding claims, for use in the treatment of haematopoietic disorders in an organism.
Claim 19
Dependent Claim
11 words
PEG-IL-6 according to claim 18 for use in promoting platelet production.
Claim 20
Dependent Claim
31 words
A pharmaceutical composition comprising a pharmaceutically acceptable solvent, diluent, adjuvant or carrier and as an active ingredient, a biologically active PEG-IL-6 as claimed in any one of claims 1 to 17.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.